Abstract 16587: Sodium Glucose Cotransporter-2 Inhibitors Post Acute Coronary Syndrome Induced New Heart Failure
Mace
DOI:
10.1161/circ.148.suppl_1.16587
Publication Date:
2023-12-19T08:08:02Z
AUTHORS (17)
ABSTRACT
Introduction: Patients with acute coronary syndrome (ACS) have an unmet need for further risk reduction in major adverse cardiovascular events (MACE) and heart failure (HF) development despite guideline-directed medical therapy. As sodium glucose cotransporter-2 inhibitors (SGLT2i) are cardioprotective, this study, we assessed the effectiveness of SGLT2i post-ACS new onset HF. Hypothesis: use improves outcomes induced Methods: We conducted a retrospective observational cohort study that included all diabetic patients admitted to main tertiary cardiology center Qatar between 1/06/2017 1/06/2021 ACS complicated by HF defined as clinical requiring diuretics during index admission, or ejection fraction (EF) <40%. divided population two groups; (1) users; (2) non-SGLT2i users. Primary were evaluated at 30 360 days, including composite ACS, hospitalization, all-cause mortality. A propensity score-matched model (1:1) was used adjust baseline characteristics groups. Cox proportional hazard regression analysis evaluate outcomes. P-value <0.05 indicated statistical significance. Results: 465 who met eligibility criteria (93% male, mean age 55±10 years, 72% Asian). Using 1:1 score matching, 78 per arm absolute standardized difference <0.1 characteristics. The post ischemia-induced resulted lower days [ 30-day: 2.6% vs. 11.5%, HR= 0.20 (0.04-0.94), P =0.041; 360-Day: 14.1% 23.1, 0.46 (0.22-0.99), P= 0.046]. Conclusions: Our findings suggest cardioprotective effects HF, which widens spectrum indications may encourage cardiologists prescribe population.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....